Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) is the leading vertically integrated pharmaceutical manufacturer in Saudi Arabia with a regional presence across 16 countries. SPIMACO specializes in providing patients in the Kingdom and the region with generic, high-quality pharmaceuticals across more than 60 therapeutic chemical classes and is the strategic partner of choice for global, regional, and local pharma manufacturers.
SPIMACO’s success is underpinned by its unparalleled asset base in Saudi Arabia and the region with facilities in the Kingdom - with its flagship site in Qassim, Saudi Arabia, spanning 150,000 sqm-, Egypt, Morocco, and Algeria (minority stake). SPIMACO boosted its manufacturing capabilities by introducing the region’s first-of-its-kind Oncology and High Potent Drugs facility. This SFDA-approved facility, supported by state-of-the-art machinery in compliance with international standards, was developed with AstraZeneca. All of this is further complemented by an extensive distribution operation in the GCC and wider MENA region supporting solid export growth.
SPIMACO has been listed on the Saudi Stock Exchange (Tadawul) since 1993 and is part of the FTSE Saudi Arabia Small Cap Index.
SPIMACO is the leading pharmaceutical manufacturer in Saudi Arabia, with a market share of 7.5% in the private sector, and the first choice for brand partners seeking exposure to the Kingdom and strategic markets.
The Group offers quality access to Saudi Arabia’s fast-growing generics pharmaceutical sector, to the Kingdom’s nascent biologics space and to a growing presence across select high-growth strategic markets.
Saudi Arabia presents strong structural growth opportunities, with growing patient base, increased chronic diseases and favourable regulatory environment
Established track record with aleading market share, outstanding production facilities, and a recognized partner of choice
Comprehensive transformation to the core of the Group to realign it to achieve our long-term strategic targets by 2027
Growing generics presence in fastgrowing, high value therapeutic areas with a well-diversified scope of biosimilar and innovative medicines
Refreshed, highly experienced management team grounded within solid corporate governance framework
Revamped organizational design and culture to foster efficiency and drive quality while being aligned with the Kingdom’s social and economic agendas
Mr. Jerome Cabannes holds a Master’s degree in Biomedical Engineering from Paul Sabatier University, France; Finance, Strategy, MA certifications from Oxford and Cambridge Universities, UK.
He has 30+ years of professional experience in healthcare industry, including leadership positions in Servier Group, BIOGARAN, Stago Group, France, and AJ Group in various geographies.
With over 22 years of experience across diverse industries and geographies, Mr. Atef Zouari previously served as CFO for Novartis Tunisia and Libya, Durrah Advanced Development Company (Durah Sugar Refinery) in Saudi Arabia, and as Regional CFO for IFFCO, a UAE-based international group.
Mr. Zouari holds an Executive MBA from the Mediterranean School of Business (MSB), Tunisia, as well as a bachelor’s degree in Finance and Accounting. He also holds a master’s degree in Banking and Financial Markets from the Institut Supérieur de Comptabilité et d'Administration des Entreprises (ISCAE), part of the University of Manouba in Tunisia.
Mr. Mohammed Alassmari has a Master’s degree in International Law from Oxford Brookes University, UK, and a Master’s in Law from the University of York, UK. He has over 24 years of experience across various sectors.
He previously held the position of Head of People Operations at Almarai and Head of HR Operations and Shared Services in Tasnee. He recently held the position of Director of HR Operations and Shared Services at Acwa Power.
Eng. Abdullah Al Rashidi brings over 2 decades of extensive expertise in the pharmaceutical manufacturing industry, having navigated diverse leadership roles across various functions during his tenure at SPIMACO. His comprehensive experience underscores a wealth of knowledge and a proven track record in steering successful initiatives within the pharmaceutical sector.
Eng. Al Rashidi holds a bachelor’s degree in Engineering – Chemical Engineering, from King Saud University, Saudi Arabia.